AUG 21, 2013 02:00 PM PDT
Claritas Genomics: The Future of Pediatric Diagnostics is Now
Presented at the Genetics and Genomics 2013 Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: CE
96 48 2330

Speakers:
  • Chief Executive Officer, Claritas Genomics
    Biography
      Dr. Milos recently joined Claritas Genomics, a newly formed company focused on pediatric molecular diagnostics emerging from Boston Children's Hospital in partnership with Life Technologies. Claritas Genomics combines the power of next-generation DNA sequencing technology with the clinical expertise of the world's best pediatric specialists to inform and improve patient care. Patrice most recently served as the Boston Site Head for Pfizer's Centers of Therapeutic Innovation and Precision Medicine Lead. The CTI model represented a new and exciting approach to drug discovery through establishment of academic medical center partnerships, including Beth Israel, Boston Children's Hospital, Tufts Medical Center, Boston University School of Medicine and Partners Healthcare, along with Pfizer to establish proof of mechanism for novel targets and pathways aiming to treat human disease. Dr. Milos previously served as the Senior Vice President and Chief Scientific Officer for Helicos BioSciences Corporation, Cambridge, MA joining in June 2007. Her expertise and extensive knowledge in the life sciences helped advance the company's efforts to develop and apply innovative and breakthrough single molecule DNA and RNA sequencing technology with recent focus on molecular diagnostics. Accomplishments included the development of the world's first and only method for direct capture and sequencing of BRCA1/2, the only method for direct sequencing of RNA as well as the establishment of collaborations with world class institutions including the Broad Institute, Harvard Medical School, Massachusetts General Hospital and the Children's Oncology Group. Patrice's previously served as Executive Director for Pfizer Global Research and Development, Groton, CT. Patrice was responsible for leadership, strategy alignment and execution of the scientific disciplines of pharmacogenomics, proteomics, metabonomics and RNA profiling applied across the Pfizer portfolio from early discovery into the marketplace. Initially joining Pfizer in 1993, Dr. Milos held numerous research positions of increasing responsibility focusing on Cardiovascular and Metabolic Disease, Pharmacogenomics, DNA Sequencing, Biomarkers and Molecular Sciences. Dr. Milos serves on the Boston Children's Hospital Technology Advisory Board, is an active NIH grant reviewer and has served on the National Advisory Council for Human Genome Research. Patrice was also pivotal in the establishment and oversight of key Pfizer strategic investments in the genomics area, most notably, the Genetic Association Information Network in partnership with NIH. She also sits on several journal editorial boards and has published and presented extensively in genomic sciences. Dr. Milos conducted post-doctoral fellowships at Brown University and Harvard University. She earned her MS and PhD degrees at Rensselaer Polytechnic Institute in Troy, NY.

    Abstract:
    Increasingly genome sequence knowledge is unraveling the complexity of rare Mendelian disorders offering hope for our children's medical care through better disease diagnosis and ultimately patient care. When combined with the emerging new sequencing technologies, allowing large scale genome analysis to move rapidly into clinical laboratories, new opportunities arise for more precise medical care. Claritas Genomics was founded to deliver on the promise of science and technology merging for medical care. Our presentation will discuss the current needs for molecular diagnostics in pediatric populations and provide a better understanding of the role Claritas plays in enabling better patient decisions. Founded as a genetic diagnostic testing company, Claritas combine the power of next-generation DNA sequencing technology with the clinical expertise of the world's best pediatric specialists to assist in informing and improving patient care. Claritas offers a full range to support physician test ordering and support needed as they care for patients, navigating an increasingly complex landscape of genetic diagnostics. Our genomic interpretive services are based on the most up to date and reliable scientific findings and our reports are designed to clearly communicate this complex genetic information. Originally Boston Children's Hospital's CLIA molecular testing laboratory, and launched as an independent CLIA/GLP laboratory in February 2013, we have an existing comprehensive menu of tests, with new next-generation sequencing-based services to be launched in the fall of 2013. Through our partnership with Life Technologies, Claritas is also well positioned to offer cutting edge advances in DNA sequencing, offering products from single gene tests through to whole exomes. Claritas also maintains a close relationship with Boston Children's and its renowned investigators, to uniquely position us to translate novel research-based discoveries into diagnostic clinical practice. Thus we aim to enable health care providers to integrate genomics into the future of their routine medical practice responsibly and Claritas takes pride in our partnership with both our ordering clinicians and the genetic researchers making discoveries that will lead to new tests and clinical knowledge.

    Show Resources
    Loading Comments...